Influence of RFC1 c.80A>G Polymorphism on Methotrexate-Mediated Toxicity and Therapeutic Efficacy in Rheumatoid Arthritis: A Meta-analysis.
Shaik Mohammad NaushadSalman A AlrokayanFahad N AlmajhdiTajamul HussainPublished in: The Annals of pharmacotherapy (2021)
RFC1 c.80 A>G is an important pharmacogenetic determinant of MTX therapy in RA. The RFC1 80A-allele robustly increased therapeutic efficacy and safety when folate was used along with MTX. Findings are relevant to decision-making in the clinical use of MTX as a treatment for RA patients harboring the RFC1 gene variant.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- ejection fraction
- ankylosing spondylitis
- newly diagnosed
- chronic kidney disease
- interstitial lung disease
- high dose
- prognostic factors
- peritoneal dialysis
- stem cells
- genome wide
- gene expression
- transcription factor
- combination therapy
- replacement therapy